Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) is a biotechnology company with a strong focus on research and development. The company leverages its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs that target viral infections and liver diseases. Based in Watertown, Massachusetts, Enanta is at the forefront of developing novel inhibitors aimed at combating the hepatitis C virus (HCV), among other conditions.
Enanta's portfolio includes several classes of direct-acting antiviral (DAA) inhibitors, such as protease inhibitors, NS5A inhibitors, and nucleotide polymerase inhibitors. These are complemented by a host-targeted antiviral (HTA) inhibitor class specifically designed against cyclophilin. One of the company's most notable achievements is the development of paritaprevir, a lead protease inhibitor that is a key component of AbbVie's approved HCV treatment regimen.
In addition to HCV, Enanta is actively pursuing treatments for other serious conditions. The company has a preclinical program targeting non-alcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage due to fat buildup. Enanta's research also extends to hepatitis B and the respiratory syncytial virus (RSV), broadening its impact on viral and liver diseases.
Enanta operates in partnership with AbbVie, which markets its protease inhibitors, while other promising drug candidates are progressing through the development pipeline. The company's commitment to innovation and strategic collaboration positions it as a significant player in the biotech industry.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has announced the presentation of data for its leading antiviral candidates EDP-235 and EDP-323 at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen. EDP-235 is a 3CL protease inhibitor aimed at treating COVID-19, while EDP-323 targets respiratory syncytial virus (RSV). Presentations will occur on April 17, with EDP-235's poster focusing on its potential for treating Long COVID, and EDP-323's poster detailing its pharmacokinetics. These developments underscore Enanta's commitment to advancing treatments for viral infections.
Enanta Pharmaceuticals (NASDAQ: ENTA) unveiled promising data on EDP-235 during the 36th International Conference on Antiviral Research in Lyon, France. EDP-235 showcases favorable safety, tolerability, and pharmacokinetics, supporting once-daily dosing without ritonavir. Preclinical studies suggest its potential to reduce COVID-19 transmission and viral rebound. The drug is currently in a Phase 2 trial (SPRINT) for non-hospitalized adults with mild to moderate COVID-19, with data expected in May 2023. Strong preclinical results highlight EDP-235's tissue penetration, and new non-nucleoside inhibitors were identified through high-throughput screening.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that data for EDP-235, its lead 3CL protease inhibitor for COVID-19, will be presented at the 36th International Conference on Antiviral Research from March 13-17, 2023, in Lyon, France. New clinical data from a Phase 1 study will be showcased, highlighting EDP-235's effectiveness in suppressing viral replication and potentially mitigating viral rebound. Key presentations include an oral presentation on March 15 and several poster presentations on March 14-15. Enanta continues to focus on developing small molecule drugs for viral infections, funded primarily through royalties from hepatitis C products.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company focused on small molecule drugs for viral infections, announced that its CEO, Jay R. Luly, Ph.D., will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:00 a.m. ET. The live webcast of the event will be available on Enanta's website, with a replay archived for 60 days. Enanta specializes in developing treatments for various viral infections, including respiratory syncytial virus (RSV), SARS-CoV-2, and hepatitis B virus (HBV). Their research is supported by royalties from hepatitis C virus (HCV) collaborations with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported a revenue of $23.6 million for its fiscal first quarter ended December 31, 2022, primarily from royalty revenue linked to AbbVie's MAVYRET/MAVIRET. The company noted a decline in royalty revenue from $27.6 million in the previous year, attributed to lower patient volumes due to COVID-19. R&D expenses decreased to $40.9 million, while G&A expenses rose to $12.7 million. Enanta completed enrollment in the Phase 2 SPRINT study of EDP-235 for COVID-19, with topline data expected in May 2023. Additionally, key data from EDP-323 for RSV is anticipated in Q2 2023.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that Jay R. Luly, Ph.D., President and CEO, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 8:40 a.m. ET. The event will be accessible via a live webcast on Enanta's website, with a replay available for 30 days post-event. Enanta specializes in developing small molecule drugs for viral infections, including candidates for RSV, COVID-19, and hepatitis B virus. Their research is funded by royalties from hepatitis C virus products developed with AbbVie, including the leading treatment regimens MAVYRET® and MAVIRET®.
Enanta Pharmaceuticals (NASDAQ: ENTA) has announced plans to report its financial results for the first fiscal quarter ended December 31, 2022, on February 7, 2023, after market close. The management will conduct a conference call at 4:30 p.m. ET to discuss these results and provide updates on ongoing research and development initiatives. Enanta focuses on developing small molecule drugs targeting viral infections, including COVID-19, RSV, and hepatitis B. It receives funding through royalties from its collaboration with AbbVie, particularly from the HCV treatment drug, Glecaprevir.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced progress on its COVID-19 and RSV programs, highlighting the ongoing Phase 2 SPRINT trial for EDP-235, a 3CL protease inhibitor, with data expected in H1 2023. New preclinical data indicates EDP-235 can prevent COVID-19 transmission. Enanta is also expanding its antiviral portfolio, announcing a new research program for SARS-CoV-2 Papain-Like Protease inhibitors and targeting dual-inhibitors for hMPV and RSV, with candidate selection planned for Q4 2023. CEO Jay R. Luly will provide updates during the J.P. Morgan Healthcare Conference on January 10, 2023.
Enanta Pharmaceuticals (NASDAQ:ENTA) will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 3:00 p.m. PT. CEO Jay R. Luly, Ph.D., will lead the presentation, which will be available via a live webcast on Enanta's website. Following the event, a replay will be accessible for 30 days. Enanta focuses on developing small molecule drugs for viral infections, including COVID-19, respiratory syncytial virus, and hepatitis B, backed by royalties from its successful hepatitis C collaborations with AbbVie.
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that CEO Jay R. Luly, Ph.D., will participate in two upcoming investor conferences. The events include a Fireside Chat at the Piper Sandler 34th Annual Healthcare Conference on November 29 at 2:00 p.m. ET, and a session at the Evercore ISI 5th Annual HealthCONx Conference on November 30 at 3:30 p.m. ET. Live webcasts will be available on Enanta's website, with replays accessible for 30 days. Enanta focuses on developing small molecule drugs for viral infections, including RSV, COVID-19, and HBV.
FAQ
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
What is the market cap of Enanta Pharmaceuticals (ENTA)?
What is the focus of Enanta Pharmaceuticals?
Where is Enanta Pharmaceuticals located?
What are some of the diseases Enanta targets?
What is paritaprevir?
Does Enanta collaborate with other companies?
What is Enanta’s approach to drug discovery?
What is NASH?
What are DAAs?
What is an HTA inhibitor?
What makes Enanta significant in the biotech industry?
